It's here! The first full episode of our new video series, 'The Dish with Johannes' is out on our Youtube channel! 🧫🔬 Full episode here 👉 https://lnkd.in/eTgUHdfd In our premiere episode, Johannes Fruehauf sits down with Katrine Bosley to hear more about her latest startup venture – DaCapo Brainscience. Katrine makes up a small number of #innovative serial #biotech entrepreneurs that call LabCentral home, making her insight invaluable to the first time #founder. Head to our YouTube channel to watch the full episode of 'The Dish with Johannes' and let us know what you think!
LabCentral
Biotechnology Research
Cambridge, Massachusetts 9,755 followers
LabCentral is the premier shared lab community for innovative biotech startups. Home to 100 teams and growing fast!
About us
LabCentral is Cambridge, MA's premier network of shared laboratory spaces and scientific communities, designed to jumpstart the launch of promising early-stage life-sciences companies. Home to 100+ great teams and growing fast! Providing first-class operational support, curated events and programming, and access to a diverse network of sponsors, LabCentral prepares entrepreneurs and scientists to accelerate scientific innovation in service of human health.
- Website
-
http://labcentral.org
External link for LabCentral
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Nonprofit
- Founded
- 2013
- Specialties
- Laboratory Services, RNAi, drug development, FDA, toxicology, probiotics, contract research laboratory, cell culture, nanotechnology, drug delivery, high throughput screening, IND, NDA, BSL-2, cancer biology
Locations
-
Primary
700 Main Street North
Cambridge, Massachusetts 02139, US
-
610 Main St
Cambridge, Massachusetts 02139, US
-
238 Main St
Cambridge, Massachusetts 02142, US
Employees at LabCentral
-
Timothy Rowe
Founder and CEO of CIC
-
Michael LaRhette
Helping entrepreneurs win and the global platforms that support them succeed by focusing on collaborative innovation and design
-
Susie Harborth
Strategy and Business Development | ex-VC & IB | COO/CFO Biotech Startups (3 Exits) | Women's Health Investor | Life Science Real Estate
-
John Harthorne
Founder and Managing Director at Two Lanterns Venture Capital
Updates
-
Navigating the world of biotech startups brings about a unique set of challenges but the right best practices can make all the difference. Our latest blog by Tim Jarrett, who specializes in resident success at LabCentral, explores key strategies to mitigate regulatory risks effectively. Check it out for insights that could make all the difference in your journey! #biotech #lifesciences #biotechstartup #startups #innovation Read more below 👇👇👇
-
It's time to Dish!! 🧫🔬 The latest full episode of our new video series, 'The Dish with Johannes' just dropped on our Youtube channel! Full episode here 👉 https://lnkd.in/gpgn6ZxE In this episode, Johannes Fruehauf sits down with Daniel Fischer, CEO & Co-Founder of Tevard Biosciences to discuss his personal connection to Tevard's mission, their work revolutionizing #tRNA therapeutics, and his learnings along the way. There's also a cameo by a very special orange guest! #TheDish #innovation #geneticdisease #Dravet #epilepsy #CEO #founder #entrepreneur #startup
-
🚨 1 WEEK AWAY 🚨 Next Tuesday #Gallery1832 presents 'Harmony & Mayhem', the latest exhibit on display at #LabCentral238 and the Bayer Co.Lab. 🎨 🖌 This art reception will feature works by abstract artists, Brittney Ciccone, sorin bica, Anthony Dyke and Susan Morrison-Dyke curated by our very own Shazia Mir. The aptly titled 'Harmony & Mayhem' exhibit brings together pieces that mesh formal blocks of color with playfully drawn interpretations of natural and stylized forms results in a harmonious composition amongst the mayhem. Special thanks to Bayer Co.Lab for sponsoring this event! RSVP below 👇 https://lnkd.in/gtWw8QvU #biotech #lifesciences #art #STEAM #Bostonart #Cambridgeart
-
Only a couple weeks until the inaugural Boston Biotech Investor Day, hosted in partnership with BioLabs and The Engine Accelerator. 💡 🤝 This invite-only event will bring together life sciences leaders and #visionary investors in the heart of #KendallSquare! 🌟 The day promises over 40 early-stage #biotech companies, 50+ firms and 80+ eager #investors engaging in a day of talks, pitches, panels, networking, and #innovation. ➡ If you're a journalist or investor interested in attending, reach out to [email protected].
Life Sciences Leaders Convene Inaugural Boston Biotech Investor Day -…
labcentral.org
-
LabCentral reposted this
🚀 We are thrilled to announce the first-ever Boston Biotech Investor Day in partnership with our collaborators LabCentral and BioLabs! 🚀 Join us on Tuesday, September 10 for an invitation-only event featuring: 🌟 40+ early-stage companies pioneering novel therapies and transformative human health technologies 💼 50+ leading investors looking to back the next wave of biotech innovation 🎤 Keynote address by Rachel Sha, CEO of Vaxess Technologies 📣 Talks, pitches, panel discussions, and plenty of networking opportunities This event is a unique opportunity to connect with startups solving some of the toughest problems in human health and the investors interested in backing them. ➡ If you're a journalist or investor interested in attending, reach out to [email protected]. #LifeSciences #Biotech #Innovation #KendallSquare #HumanHealth
-
Despite having roots in Italy, Luca Giani & his co-founders chose to build Ilios Therapeutics in Cambridge –to them, the choice was obvious. 💡 Here, they've successfully leveraged the connections & resources from both the LabCentral and Harvard Innovation Labs communities. Beyond that, their proximity to accelerators such as MassChallenge, MassBioDrive and Nucleate helped them form their lean, mean team. 💪 Want to hear more of Luca's chat with Johannes Fruehauf? Catch the full episode of The Dish here: https://lnkd.in/eKDtwVZ6 #biotech #lifesciences #entrepreneurship #startup #Boston #Cambridge
-
🗣Calling all our biotech entrepreneurs! 🗣 This afternoon NCI SBIR Development Center is hosting an informational webinar focused on PHS 2025-I Contract Solicitation from 2:00-3:30PM. 💡 Attendees will receive a detailed overview describing how this opportunity provides early-stage funding to small businesses developing cancer technologies. There will also be a discussion on the 13 NCI topics identified by the National Cancer Institute (NCI). A Q&A session between attendees and panelists will follow the presentation. Register here: https://bit.ly/3MBoQEl
Don't forget to join Thursday's webinar on the FY25 NCI #SBIR Contract Solicitation! Contracting experts will answer your questions following a presentation of this year's funding opportunity and topic areas. https://lnkd.in/gPnBMi5Q
-
Huge thanks to everyone who came to last week's LabCentral Ignite Golden Ticket launch event. It was a pleasure hearing from each of the #goldenticket finalists! We can't wait to hear everyone's full pitch come September 24th –it's sure to be an exciting evening! ✨
It's our favorite time of year again! We're thrilled to announce this year's finalists for the LabCentral Ignite Golden Ticket! 🏆 Our Golden Ticket finalists are: CircNova, Inc, Genesist, Interon Laboratories, Inc., Nanoplex, PhagePro, Coagulo Medical Technologies, Inc., DaCapo Brainscience, DoriNano, Lybra Bio, Matrisome Bio, and Neoclease. Designed to uplift and celebrate companies led by underrepresented communities in #biotech industry, our Golden Tickets are specifically given to companies founded by women & people of color. This year we're excited to have the opportunity to award six golden tickets with the support of our sponsors. Winners of the Golden Ticket receive $50,000 credit towards space available at LabCentral's flagship site in Kendall Square. On top of that, winners gain access to the Ignite Golden Ticket #fellowship, which supercharges their ecosystem, providing them with the #network, #resources and #support needed to succeed in the industry. A huge thank you to our sponsors for their continued commitment to Ignite's mission: Bayer, Bristol Myers Squibb, Eli Lilly and Company, Novartis, Pfizer, Takeda, BioMarin Pharmaceutical Inc., Silicon Valley Bank, a division of First Citizens Bank, and Wilson Sonsini Goodrich & Rosati, and EisnerAmper
-
+1
-
🔍 Eye spy LabCentral lab space 🔎 Congratulations to Floris Engelhardt, John Vroom, Mark Bathe and the whole Kano Therapeutics team! It has been a pleasure to watch your company grow and move through our spaces. We can't wait to see what this latest achievement brings for your team. 🎉 #innovation #biotech #lifesciences #genomicmedicine #entrepreneurship
𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗞𝗮𝗻𝗼 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗼𝗻 𝘁𝗵𝗲𝗶𝗿 $𝟳.𝟭𝟱𝗺 𝘀𝗲𝗲𝗱 𝗿𝗼𝘂𝗻𝗱: 𝗽𝗶𝗼𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗳𝗿𝗼𝗻𝘁𝗶𝗲𝗿 𝗼𝗳 𝗴𝗲𝗻𝗲 𝗶𝗻𝘀𝗲𝗿𝘁𝗶𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀🧬 Thrilled to announce our investment in Kano Therapeutics, a cutting-edge Massachusetts Institute of Technology spinout that is redefining the landscape of gene insertion therapies. Kano’s innovative approach leverages the flexibility of single-stranded DNA (ssDNA) to improve the delivery and efficacy of genetic medicines. Gene insertion therapies have the potential to revolutionize the treatment of inherited diseases and enhance the effectiveness of cell therapies for cancer and autoimmune conditions. However, the rigidity of traditional double-stranded DNA (dsDNA) has posed significant challenges in packaging and delivery. Kano Therapeutics addresses this issue by utilizing ssDNA, which is 50 times more flexible than dsDNA. This flexibility not only facilitates better integration into target cells but also reduces cellular toxicity and enhances editing accuracy. Kano’s groundbreaking work is set to unlock new possibilities in the field of non-viral genetic therapies. By focusing on optimizing the DNA payload rather than just the delivery mechanisms, Kano is setting a new standard in the industry. Their partnership with Novo Nordisk and the $7.15 million seed funding round, co-led by Engine Ventures and Vsquared Ventures, underscores the enormous potential of their approach. Congratulations to Floris Engelhardt, John Vroom and the entire Kano team! Read more about their incredible technology on Endpoints (link in comments).